Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946767 | 1.00 | PARP15 (0.50) | PARP15PARP10PARP2MAOBNR1H4 | |
| SCHEMBL3946765 | 1.00 | PARP15 (0.50) | PARP15PARP10PARP2MAOBNR1H4 | |
| SCHEMBL4088139 | 0.93 | PARP15 (0.43) | PARP15PARP10PARP2MAOBCYP1A1 | |
| SCHEMBL4088142 | 0.93 | PARP15 (0.43) | PARP15PARP10PARP2MAOBCYP1A1 | |
| SCHEMBL4088145 | 0.93 | PARP15 (0.43) | PARP15PARP10PARP2MAOBCYP1A1 | |
| SCHEMBL3945141 | 0.90 | CYP1A1 (0.44) | MAOBCYP1A1CYP1B1ALOX5 | |
| SCHEMBL3945137 | 0.90 | CYP1A1 (0.44) | MAOBCYP1A1CYP1B1ALOX5 | |
| SCHEMBL3945139 | 0.90 | CYP1A1 (0.44) | MAOBCYP1A1CYP1B1ALOX5 | |
| SCHEMBL3941234 | 0.90 | NR1H4 (0.44) | PARP15PARP10PARP2MAOBNR1H4 | |
| SCHEMBL3941238 | 0.90 | NR1H4 (0.44) | PARP15PARP10PARP2MAOBNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | PARP15 1899/4885PARP10 1526/4885PARP2 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.